We collect cookies to analyze our website traffic and performance; we never collect any personal data. Cookie Policy
Accept
The Tycoon Herald
  • Trending
  • World
  • Politics
  • Business
    • Business
    • Economy
    • Real Estate
    • Money
    • Crypto / NFT
  • Innovation
  • Lifestyle
    • Lifestyle
    • Food
    • Travel
    • Fashion
    • Leadership
  • Health
  • Sports
  • Entertainment
Reading: Nykode Therapeutics Broadcasts Issuance of Key Patent Overlaying Individualized Neoantigen Based mostly Vaccines By Investing.com
Sign In
The Tycoon HeraldThe Tycoon Herald
Font ResizerAa
Search
  • Trending
  • World
  • Politics
  • Business
    • Business
    • Economy
    • Real Estate
    • Money
    • Crypto / NFT
  • Innovation
  • Lifestyle
    • Lifestyle
    • Food
    • Travel
    • Fashion
    • Leadership
  • Health
  • Sports
  • Entertainment
Have an existing account? Sign In
Follow US
© Tycoon Herald. All Rights Reserved.
Nykode Therapeutics Broadcasts Issuance of Key Patent Overlaying Individualized Neoantigen Based mostly Vaccines By Investing.com
The Tycoon Herald > Business > Nykode Therapeutics Broadcasts Issuance of Key Patent Overlaying Individualized Neoantigen Based mostly Vaccines By Investing.com
Business

Nykode Therapeutics Broadcasts Issuance of Key Patent Overlaying Individualized Neoantigen Based mostly Vaccines By Investing.com

Tycoon Herald
By Tycoon Herald 5 Min Read Published August 14, 2024
Share
SHARE

Nykode Therapeutics Broadcasts Issuance of Key Patent Overlaying Individualized Neoantigen Based mostly Vaccines By Investing.com

OSLO, Norway, Aug. 14, 2024 (GLOBE NEWSWIRE) — Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical firm devoted to the invention and improvement of novel immunotherapies, immediately introduced that the US Patent and Trademark Workplace (USPTO) has issued U.S. Patent No. 12,059,459, entitled, Therapeutic Anticancer Neoepitope Vaccine.

The newly issued patent describes Nykode’s totally individualized neoantigen primarily based vaccine, VB10.NEO, which is in improvement for the remedy of regionally superior or metastatic stable tumours. The 20 12 months expiration date of this patent is January 5, 2037. Associated patents had been beforehand granted to the corporate in Russia, India, and Australia.

Michael Engsig, CEO of Nykode, mentioned,  We’re more than happy with the granting of this necessary patent within the U.S., a key marketplace for Nykode. Repeatedly increasing our patent safety is a core technique for us. The granting of this patent is a testomony to the world-class innovation happening in Nykode’s labs. We stay devoted to pushing the boundaries of what is attainable in medication, bringing hope to sufferers and their households across the globe.

About VB10.NEO
VB10.NEO is a proprietary individualized neoantigen vaccine in improvement for the remedy of regionally superior or metastatic stable tumors beneath an unique, worldwide medical collaboration with Genentech, a member of the Roche Group. The vaccine is designed to be produced on-demand in accordance with the neoantigen profile of a person affected person. Neoantigens are proteins generated by tumor-specific mutations not current in regular tissues and are thus a sexy goal for most cancers immunotherapy as they could be acknowledged as overseas by the immune system.

Nykode is at the moment conducting a medical examine evaluating VB10.NEO: VB N-02, an open-label Part 1b, dose-escalation examine of the protection and antigen-specific immune responses elicited by VB10.NEO together with Roche’s checkpoint inhibitor atezolizumab in sufferers with regionally superior and metastatic tumors (NCT05018273).

About Nykode Therapeutics
Nykode Therapeutics is a clinical-stage biopharmaceutical firm devoted to the invention and improvement of novel immunotherapies with a give attention to the remedy of most cancers and autoimmune ailments. Nykode’s modular vaccine expertise particularly targets antigens to antigen presenting cells (APC), which have been proven to induce a broad, robust and long-lasting antigen particular immune response in most cancers, which correlates with medical responses.

Nykode’s lead product candidates are VB10.16, a therapeutic vaccine for the remedy of HPV16 induced malignancies which demonstrated favorable security and efficacy outcomes from its Part 2 trial for the remedy of cervical most cancers. VB10.16 is being expanded into a number of trials for remedy of head and neck most cancers and cervical most cancers. VB10.NEO, an individualized most cancers neoantigen vaccine, is solely out-licensed to Genentech, a member of the Roche Group.

The Firm’s partnerships embrace Genentech inside oncology and a multi-target collaboration with Regeneron (NASDAQ:) in oncology and infectious ailments.

Nykode can also be using its APC-targeted expertise to create an inverse vaccine platform for the potential use in autoimmune problems, organ transplant rejections, anti-drug antibody reactions and allergy.

Nykode Therapeutics’ shares are traded on the Oslo Inventory Change (OSE: NYKD). Additional details about Nykode Therapeutics may be discovered at http://www.nykode.com.

Ahead-looking statements for Nykode Therapeutics

This announcement and any supplies distributed in reference to this announcement could comprise sure forward-looking statements. By their nature, forward-looking statements contain threat and uncertainty as a result of they mirror the corporate’s present expectations and assumptions as to future occasions and circumstances that won’t show correct. Quite a lot of materials components may trigger precise outcomes and developments to vary materially from these expressed or implied by these forward-looking statements.

Contact for Nykode Therapeutics ASA:

Head of Investor Relations, Alexandra Deschner
Nykode Therapeutics ASA
[email protected]

Nykode Therapeutics ASA

Oslo Science Park
Gaustadalléen 21
N-0349 Oslo, Norway

Supply: Nykode Therapeutics ASA

You Might Also Like

Russia for Business: Experts Who Help Drive Decisions

The Quiet Shift in America’s Workforce: Why Side Hustles Are Becoming Essential for Women Over 40

Joseph Safina’s Driven Becomes Amazon Bestseller, Blending High Finance with High Speeds

Fashion Designer Hyeonseo Irene Park: Redefining Menswear Through Originality and Collaboration

From Pattaya to the World: Bryan Flowers’ Unstoppable Rise as a Global Entrepreneur

TAGGED:AnnouncesBasedCoveringIndividualizedInvesting.comIssuancekeyNeoantigenNykodepatentTherapeuticsVaccines
Share This Article
Facebook Twitter Email Copy Link Print
Scorching Honey Wings Recipe | Candy And Spicy Rooster Wings
Food

Scorching Honey Wings Recipe | Candy And Spicy Rooster Wings

PUBLISHED October 22, 2025· MODIFIED October 22, 2025 · by the writer listed within the recipe card 1255 phrases. · About 7 minutes to learn this text.· This put up…

By Tycoon Herald 11 Min Read
Sandro Tonali new contract: Newcastle midfielder indicators deal till summer time of 2029 with possibility of additional 12 months
October 22, 2025
How Corporations Are Remodeling Industries with Utilized Intelligence – AI Time Journal – Synthetic Intelligence, Automation, Work and Business
October 22, 2025
Victoria Beckham Did not Open up to David Amid Consuming Dysfunction
October 22, 2025
VP Vance tries to progress Gaza ceasefire. And, White Home demolition attracts critics
October 22, 2025

You Might Also Like

Astana International Forum 2025: “Connecting Minds, Shaping the Future”
BusinessTrending

Astana International Forum 2025: “Connecting Minds, Shaping the Future”

By Tycoon Herald 3 Min Read
Investment success: GP Fatih Marketing Research Co LLC and the gold dream in Africa
BusinessTrending

Investment success: GP Fatih Marketing Research Co LLC and the gold dream in Africa

By Tycoon Herald 4 Min Read
Gaza residents stream dwelling to the north after hostage breakthrough By Reuters
Business

Gaza residents stream dwelling to the north after hostage breakthrough By Reuters

By Tycoon Herald 6 Min Read

More Popular from Tycoon Herald

MEET THE FATHER OF COADUNATE ECONOMIC MODEL
BusinessTrending

MEET THE FATHER OF COADUNATE ECONOMIC MODEL

By Tycoon Herald 2 Min Read
Woman Sentenced to 7 Days in Jail for Walking in Yellowstone’s Thermal Area

Woman Sentenced to 7 Days in Jail for Walking in Yellowstone’s Thermal Area

By Tycoon Herald
Empowering Fintech Innovation: Swiss Options Partners with Stripe to Transform Digital Payments
InnovationTrending

Empowering Fintech Innovation: Swiss Options Partners with Stripe to Transform Digital Payments

By Tycoon Herald 7 Min Read
Fashion

My Watch Assortment: A 40-ish Piece Journey from Casio Goals to Rolex Actuality | FashionBeans

We independently consider all beneficial services. Any services or products put ahead seem in no specific…

By Tycoon Herald
Entertainment

Glen Powell’s Going Again to College to Make Dad and mom Proud, End What He Began

Play video content material TMZ.com Glen Powell's crushing it in Hollywood -- however he is obtained…

By Tycoon Herald
Trending

U.S. Blew Up a C.I.A. Post Used to Evacuate At-Risk Afghans

A controlled detonation by American forces that was heard throughout Kabul has destroyed Eagle Base, the…

By Tycoon Herald
Leadership

Northern Lights: 17 Best Places To See Them In 2021

Who doesn’t dream of seeing the northern lights? According to a new survey conducted by Hilton, 59% of Americans…

By Tycoon Herald
Real Estate

Exploring Bigfork, Montana: A Little Town On A Big Pond

Bigfork, Montana, offers picturesque paradise in the northern wilderness. National Parks Realty With the melting of…

By Tycoon Herald
Leadership

Leaders Need To Know Character Could Be Vital For Corporate Culture

Disney's unique culture encourages young employees to turn up for work with smiles on their faces.…

By Tycoon Herald
The Tycoon Herald

Tycoon Herald: Your instant connection to breaking stories and live updates. Stay informed with our real-time coverage across politics, tech, entertainment, and more. Your reliable source for 24/7 news.

Company

  • About Us
  • Newsroom Policies & Standards
  • Diversity & Inclusion
  • Careers
  • Media & Community Relations
  • WP Creative Group
  • Accessibility Statement

Contact Us

  • Contact Us
  • Contact Customer Care
  • Advertise
  • Licensing & Syndication
  • Request a Correction
  • Contact the Newsroom
  • Send a News Tip
  • Report a Vulnerability

Terms of Use

  • Digital Products Terms of Sale
  • Terms of Service
  • Privacy Policy
  • Cookie Settings
  • Submissions & Discussion Policy
  • RSS Terms of Service
  • Ad Choices
© Tycoon Herald. All Rights Reserved.
Welcome Back!

Sign in to your account

Lost your password?